5 citations
,
June 2001 in “Annals of Internal Medicine” Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.
11 citations
,
January 2019 in “Acta Dermato Venereologica” Omalizumab may cause hair loss.
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
April 2019 in “Journal of Investigative Dermatology” Blocking LFA-1 prevents hair loss in mice.
10 citations
,
October 2019 in “Australasian Journal of Dermatology” Secukinumab effectively treated a difficult case of folliculitis decalvans.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
1 citations
,
March 2024 in “BioDrugs” Biologics for severe asthma have known side effects, but some new risks need more study.
July 2024 in “Journal of Investigative Dermatology”
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
37 citations
,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
1 citations
,
July 2025 in “Diagnostics” Dupilumab users have a higher risk of developing alopecia areata.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
2 citations
,
April 2024 in “Journal of International Medical Research” Secukinumab and acitretin together may quickly and effectively treat severe generalized pustular psoriasis.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
19 citations
,
December 2008 in “Arthritis Care & Research” The decision board effectively helps lupus nephritis patients in Brazil choose treatments by clearly presenting options and side effects.
147 citations
,
October 2021 in “Cancer Communications” RC48 shows promise for treating certain advanced cancers, but more research is needed.
10 citations
,
October 2024 in “Dermatology Practical & Conceptual” Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology” November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
September 2024 in “Current Oncology” Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.
23 citations
,
January 2012 in “International Food Research Journal” Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
25 citations
,
May 2019 in “Biologics” Dupilumab can cause rare side effects like a rash on the face and neck.
January 2024 in “Journal of Clinical Rheumatology and Immunology” Monitor for early signs of myelosuppression, like hair loss, in patients on azathioprine to manage side effects.